Joint Formulary & PAD

Formulary Search

I agree that in using this database I understand that this platform only provides guidance on local prescribing policy and that all prescribing decisions are ultimately the responsibility of the clinician.

Search

A-Z of Drugs : A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

A-Z of Drugs

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Search Results : Clostridioides difficile (Vancomycin hydrochloride - Clostridioides difficile)

Records returned : 3 (on 29 May 2025 at 12:43:00). Return to search results for ' Clostridioides difficile '.

Show Icon and Status Keys

Drug
Indication
Status
Restrictions/Comments
Formulary Status
Links
Status :
Green
Formulations :
  • Capsules
Restrictions / Comments:

Important
Restricted Use - for use when indicated by local trust antimicrobial guidelines, NICE condensed summary table of antimicrobial guidance or specialist microbiology recommendation. The APC notes that although current NICE guidelines recommend vancomycin first line for treatment of C diff, it is recognised that this was based on cost and in exceptional cases when a liquid is required, fidaxomicin granules are appropriate to prescribe as a licensed preparation that supports timely treatment.
 
Links :
SPC
R
Status :
Green
Formulations :
  • Oral suspension
  • Tablets
Restrictions / Comments:

Important
Granules (for oral suspension) should be used in patients requiring a liquid preparation. Restricted Use - for use when indicated by local trust antimicrobial guidelines, NICE condensed summary table of antimicrobial guidance or specialist microbiology recommendation. For any patient requiring a liquid preparation, fidaxomicin granules should be prescribed. The APC notes that although current NICE guidelines recommend vancomycin first line, it is recognised that this was based on cost and in exceptional cases when a liquid is required, fidaxomicin granules are appropriate to prescribe as a licensed preparation that supports timely treatment.
 
Links :
SPC
R
Status :
Non Formulary
Formulations :
  • Not Specified
Restrictions / Comments:

Important
The Surrey Heartlands integrated care system Area Prescribing Committee (APC) agreed with NICE recommendation not to use bezlotoxumab to prevent recurrence of C. Difficile infection because it is not cost effective. Bezlotoxumab will be given a NON-FORMULARY traffic light status for this indication.
 
Links :
SPC
NFD1